Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- 4 hours ago
- 1 min read
06/08/2026
Biogen completed the acquisition of RayThera to strengthen its immunology pipeline (Ref)
Biogen announced the completion of its acquisition of RayThera a biotechnology company focused on discovering and developing small-molecule therapies in immunology.
The acquisition strengthened Biogen’s growing immunology portfolio and added multiple assets with potential to treat immune-mediated conditions across a range of indications.
The lead program entered Phase 1 development in July 2026.
Ono Pharmaceutical entered into a drug discovery partnership with Mediar Therapeutics to create novel antibody therapeutics for fibro-inflammatory diseases (Ref)
Ono Pharmaceutical announced that it had entered into a drug discovery partnership and option agreement with Mediar Therapeutics to create novel antibody therapeutics for fibro-inflammatory diseases.
Under the terms of the agreement, Ono and Mediar agreed to collaborate to discover and create antibody drug candidates against fibro-inflammatory diseases.
Mediar would conduct research activities leveraging its antibody discovery capabilities and biological insights derived from its fibrosis-focused research platform.
Ono would have an exclusive worldwide option right to select antibody drug candidates created through the partnership for further development, manufacturing and commercialization.